The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors
Drug Resistance Updates · 2025-09 · 82 · 101273
DOI: 10.1016/j.drup.2025.101273 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025-09. Verfasst von Xinhao Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, 1 East Jianshe Road, Zhengzhou 450000, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Cancer-Associated Fibroblasts, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 382 Literaturangaben. Gefördert von: Postdoctoral Research Foundation of China, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Drug resistance remains a formidable barrier in modern oncology, undermining the efficacy of the current therapeutic regimens. As pivotal stromal constituents within tumor ecosystems, cancer-associated fibroblasts (CAFs) have emerged as critical mediators of treatment resistance through multifaceted mechanisms. In this review, we summarize the historical progression of research on CAFs and drug resistance, and highlight the recent discoveries related to CAF biomarkers and their functions associated with drug resistance. Furthermore, we discuss the relationship between CAF heterogeneity, secretion, autophagy, and senescence and their contributions to the evolution of drug resistance. Additionally, we provide a detailed explanation of how CAFs contribute to the development of drug resistance in primary tumors, including mechanisms such as immune suppression and evasion, promotion of tumor stemness, angiogenesis, extracellular matrix remodeling, and metabolic reprogramming. We also explored the role of CAFs in metastatic tumors and their association with drug resistance at various metastatic sites, including lymph nodes, brain, lungs, peritoneum, bone, and liver. Finally, we summarize the advancements in clinical trials targeting CAFs, the emerging research on potential therapeutic targets, and anticipating future trends in this area.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, 1 East Jianshe Road, Zhengzhou 450000, China.
- Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
- Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, 1 East Jianshe Road, Zhengzhou 450000, China. Electronic address: doctorlizhen@126.com.
- Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. Electronic address: zlyyliuying1664@zzu.edu.cn.
- Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, 1 East Jianshe Road, Zhengzhou 450000, China. Electronic address: sxyang@zzu.edu.cn.
Förderung
- Postdoctoral Research Foundation of China
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Wang, Y., Cui, W., Li, D., Song, J., Li, Z., Liu, Y., & Yang, S. (2025). The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors. Drug Resistance Updates, 82, 101273. https://doi.org/10.1016/j.drup.2025.101273
Vancouver
Zhang X, Wang Y, Cui W, Li D, Song J, Li Z, et al. The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors. Drug Resistance Updates. 2025;82:101273. doi:10.1016/j.drup.2025.101273
BibTeX
@article{Zhang2025,
author = {Zhang, Xinhao and Wang, Yuhang and Cui, Wenming and Li, Danyang and Song, Junmin and Li, Zhen and Liu, Ying and Yang, Shuaixi},
title = {The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors},
journal = {Drug Resistance Updates},
year = {2025},
volume = {82},
pages = {101273},
doi = {10.1016/j.drup.2025.101273}
}
EUVIMED